|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1995; 25:218-223 © 1995 by the American College of Cardiology Foundation |
Cardiology Department, Green Lane Hospital, Auckland, New Zealand.
OBJECTIVES. This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction. BACKGROUND. Patency of the infarct-related artery is an important determinant of prognosis after myocardial infarction. The incidence of late reocclusion and the effects of antiplatelet therapy are unknown. METHODS. To investigate the importance of antiplatelet therapy for the prevention of late reocclusion, 215 patients who had a patent infarct-related artery 4 weeks after myocardial infarction were randomized in a double-blind manner to receive either a combination of 25 mg of aspirin and 200 mg of dipyridamole twice daily or placebo. One hundred fifty-four patients underwent further coronary arteriography 1 year later. RESULTS. At 1 year, 38 (25%) of 154 patients had reocclusion of the infarct-related artery; 18 (23%) of 79 patients receiving aspirin and dipyridamole had late reocclusion versus 20 (27%) of 75 who received placebo (p = NS). The rate of reocclusion was related to the severity of the residual coronary artery stenosis at 4 weeks (< 50% stenosis 9.2%; 50% to 69% stenosis 11.6%; 70% to 89% stenosis 30.4%; > or = 90% stenosis 70%, p < 0.01). The majority of reocclusions were silent, and only 17 (45%) of 38 were clinically associated with further infarction. There were no differences for a hierarchic end point of cardiac death, myocardial infarction or revascularization (14.8% aspirin and dipyridamole vs. 17.8% placebo). CONCLUSIONS. Late reocclusion of the patent infarct-related artery is a frequent event, occurring in 25% of patients. Antiplatelet therapy with the combination of aspirin and dipyridamole does not alter the overall rate of late reocclusion. Other strategies are required to reduce late reocclusion.
This article has been cited by other articles:
|
|
 |
|
  M. A. Brouwer, P. J.P.C. van den Bergh, W. R.M. Aengevaeren, G. Veen, H. E. Luijten, D. P. Hertzberger, A. J. van Boven, R. P.J.W. Vromans, G. J.H. Uijen, and F. W.A. Verheugt Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Circulation, August 6, 2002; 106(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Grines, D. R. Westerhausen Jr, L. L. Grines, J. T. Hanlon, T. L. Logemann, M. Niemela, W. D. Weaver, M. Graham, J. Boura, W. W. O'Neill, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: The air primary angioplasty in myocardial infarction study J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1713 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Van de Werf New aspects of pharmacological reperfusion: from macro- to microlysis Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C62 - C68. [Abstract] [PDF]
|
|
|
|
|
|
D. Scrutinio, C. Cimminiello, E. Marubini, M. Vittoria Pitzalis, M. Di Biase, P. Rizzon, and the STAMI Group Ticlopidine versus aspirin after myocardial infarction (stami) trial J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1259 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Barbash, Y. Birnbaum, K. Bogaerts, M. Hudson, E. Lesaffre, Y. Fu, S. Goodman, K. Houbracken, K. Munsters, C. B. Granger, et al. Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction : An Analysis of Outcome and Treatment Choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) Studies Circulation, February 20, 2001; 103(7): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Grines, D. A. Cox, G. W. Stone, E. Garcia, L. A. Mattos, A. Giambartolomei, B. R. Brodie, O. Madonna, M. Eijgelshoven, A. J. Lansky, et al. Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction N. Engl. J. Med., December 23, 1999; 341(26): 1949 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bauters, M. Delomez, E. Van Belle, E. McFadden, J.-M. Lablanche, and M. E. Bertrand Angiographically Documented Late Reocclusion After Successful Coronary Angioplasty of an Infarct-Related Lesion Is a Powerful Predictor of Long-Term Mortality Circulation, May 4, 1999; 99(17): 2243 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White and F. J. J. Van de Werf Thrombolysis for Acute Myocardial Infarction Circulation, April 28, 1998; 97(16): 1632 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Smalling and H. V. Anderson Pathophysiological Insight Into the Possible Optimal Therapies for Acute Myocardial Infarction and Unstable Angina Circulation, January 13, 1998; 97(1): 10 - 11. [Full Text] [PDF]
|
|
|
|
|
|
F. Nijland, O. Kamp, F. W.A. Verheugt, G. Veen, and C. A. Visser Long-term Implications of Reocclusion on Left Ventricular Size and Function After Successful Thrombolysis for First Anterior Myocardial Infarction Circulation, January 7, 1997; 95(1): 111 - 117. [Abstract] [Full Text]
|
|
|
|
|
|
E. Falk, P. K. Shah, and V. Fuster Coronary Plaque Disruption Circulation, August 1, 1995; 92(3): 657 - 671. [Full Text]
|
|
|
|
|
|
F. Van de Werf Thrombolysis for Acute Myocardial Infarction : Why Is There No Extra Benefit After Hospital Discharge? Circulation, June 15, 1995; 91(12): 2862 - 2864. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
